Cargando…

Incidence and Risk Factors of Pneumonitis in Patients with Non-Small Cell Lung Cancer: An Observational Analysis of Real-World Data

INTRODUCTION: The incidence of pneumonitis, a treatment-related adverse event (AE) in non-small cell lung cancer (NSCLC) patients, has been studied in the United States mostly through clinical trials and retrospective chart reviews. Few analyses of real-world data have been published. This study of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tyczynski, Jerzy E., Potluri, Ravi, Kilpatrick, Ryan, Mazumder, Debasish, Ghosh, Anirban, Liede, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593090/ https://www.ncbi.nlm.nih.gov/pubmed/33909273 http://dx.doi.org/10.1007/s40487-021-00150-8

Ejemplares similares

Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States
por: Liede, Alexander, et al.
Publicado: (2023)

Evaluating Pneumonitis Incidence in Patients with Non–small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data
por: Liu, Qi, et al.
Publicado: (2023)

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
por: Tiu, Bruce C, et al.
Publicado: (2022)

High Incidence of EGFR Mutations in Pneumonic-Type Non-Small Cell Lung Cancer
por: Liu, Jun, et al.
Publicado: (2015)

Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data
por: Kim, Christopher, et al.
Publicado: (2018)

Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications
por: Hindocha, Sumeet, et al.
Publicado: (2021)

Radiation Recall Pneumonitis Anticipates Bilateral Immune-Induced Pneumonitis in Non-Small Cell Lung Cancer
por: Torresan, Sara, et al.
Publicado: (2023)

Comparison Between Health Insurance Claims and Electronic Health Records (EHRs) for Metastatic Non-small-cell Lung Cancer (NSCLC) Patient Characteristics and Treatment Patterns: A Retrospective Cohort Study
por: Choi, Yookyung Christy, et al.
Publicado: (2021)

The Pathology of the Pneumonic Lung
por: Sturges, Octavius
Publicado: (1873)

The Toxicity of Pneumonic Lungs
Publicado: (1918)

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
por: Gatti-Mays, Margaret, et al.
Publicado: (2021)

Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes
por: Taboada, Rodrigo G, et al.
Publicado: (2022)

Real-world analysis of insurance churn among young adults with schizophrenia using the Colorado All-Payer Claims Database
por: Pesa, Jacqueline, et al.
Publicado: (2022)

Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study
por: Yuan, Jing, et al.
Publicado: (2022)

High incidence of radiation pneumonitis in lung cancer patients with chronic silicosis treated with radiotherapy
por: Shen, Tianle, et al.
Publicado: (2019)

Treatment evolution for metastatic castration‐resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real‐world data
por: Flaig, Thomas W., et al.
Publicado: (2015)

Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer
por: Kim, Kyeong-Hyun, et al.
Publicado: (2013)

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience
por: Altan, Mehmet, et al.
Publicado: (2023)

Acute exacerbation of fibrotic hypersensitivity pneumonitis: incidence and outcomes
por: Kang, Jieun, et al.
Publicado: (2021)

Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study
por: Tzilas, Vasilios, et al.
Publicado: (2020)

THE SPECIFIC POLYSACCHARIDE CONTENT OF PNEUMONIC LUNGS
por: Frisch, A. W., et al.
Publicado: (1942)

Real-world treatment patterns of rheumatoid arthritis in Brazil: analysis of DATASUS national administrative claims data for pharmacoepidemiology studies (2010–2020)
por: Birck, Marina G., et al.
Publicado: (2023)

Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer
por: Saito, Satoshi, et al.
Publicado: (2020)

Factors predicting radiation pneumonitis in locally advanced non-small cell lung cancer
por: Kim, Myungsoo, et al.
Publicado: (2011)

Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies—pharmacovigilance database analysis with real-world data validation
por: Guo, Xue-Jun, et al.
Publicado: (2023)

Further Notes on the Incidence of Pneumonic Plague Cases in Gaya (Bihar)
por: Seal, S. C., et al.
Publicado: (1949)

Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy
por: Doshita, Kosei, et al.
Publicado: (2022)

The Value of Next-Generation Sequencing for Treatment in Non-Small Cell Lung Cancer Patients: The Observational, Real-World Evidence in China
por: Zhang, Yan, et al.
Publicado: (2020)

Association of lung fluorodeoxyglucose uptake with radiation pneumonitis after concurrent chemoradiation for non-small cell lung cancer
por: Yue, Jinbo, et al.
Publicado: (2017)

Hypersensitivity pneumonitis: a complex lung disease
por: Riario Sforza, Gian Galeazzo, et al.
Publicado: (2017)

Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
por: Chao, Yencheng, et al.
Publicado: (2022)

Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer
por: Hassanzadeh, Comron, et al.
Publicado: (2020)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
por: Hao, Yuxuan, et al.
Publicado: (2022)

Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
por: Fujimoto, Daichi, et al.
Publicado: (2023)

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Atezolizumab Post Chemo-Radiation
por: Saade, Lili Jose, et al.
Publicado: (2023)

Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting
por: Liang, Huifang, et al.
Publicado: (2019)

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
por: Lim, Sun Min, et al.
Publicado: (2020)

STUDIES ON THE PNEUMONIC EXUDATE : II. THE PRESENCE OF ENZYME AND ANTIENZYME IN THE PNEUMONIC LUNG. LOCAL FERMENT-ANTIFERMENT BALANCE.
por: Lord, Frederick T., et al.
Publicado: (1921)

STUDIES ON THE PNEUMONIC EXUDATE : I. EFFECT OF PRESERVATION, TEMPERATURE, DIALYSIS, AND SALT CONCENTRATION ON THE ENZYME IN THE PNEUMONIC LUNG.
por: Lord, Frederick T., et al.
Publicado: (1921)

Pneumonitis
por: Napier, L. Everard, et al.
Publicado: (1942)

Cannot write session to /tmp/vufind_sessions/sess_mf974c8r44d2j0f1m0nct734bl